Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 22Neoplasms 17Neoplasm Metastasis 16Breast Neoplasms 16Triple Negative Breast Neoplasms 10Colorectal Neoplasms 9Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Melanoma 5Carcinoma, Pancreatic Ductal 5Adenocarcinoma 5Small Cell Lung Carcinoma 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Rectal Neoplasms 3Peritoneal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Hodgkin Disease 3Fallopian Tube Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Ductal Adenocarcinoma 2Nasopharyngeal Carcinoma 2

Interventions

Cisplatin 2vactosertib 1fludarabine 1enzalutamide 1bintrafusp alfa protein, human 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1LY3300054 1Gemcitabine 1Fenretinide 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Camurati-Engelmann Syndrome × 130-nm albumin-bound paclitaxel × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡